EUVIMEDEUVIMED entdecken
Crossref

From Case Reports to Cohort Studies: The Many Faces of Clinical Research in Thrombosis and Haemostasis

Florian Langer, Heiko Rühl, Manuela Albisetti

Hämostaseologie · 01.04.2026 · 46 (02) · 96-98

DOI: 10.1055/a-2785-1481 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hämostaseologie, erschienen am 01.04.2026. Verfasst von Florian Langer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Zentrum für Onkologie, II. Medizinische Klinik und Poliklinik (Gerinnungsambulanz und Hämophiliezentrum), Universitätsklinikum Hamburg-Eppendorf, Ham….

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dear Readers, After an inspiring GTH Annual Meeting in Bonn, accompanied by an excellent collection of invited review articles, we are delighted to welcome you to this issue featuring original research contributions. Many innovative research projects and clinical trials begin with observations in individual patients. Well-described case reports are not only worth publishing; they are also an integral part of scientific advancement. In this issue of HÄMOSTASEOLOGIE – Progress in Haemostasis , you will find a vibrant display of interdisciplinary and collaborative research in clinical thrombosis and haemostasis. Follow us on a fascinating journey through the multifaceted presentations of thrombotic and haemorrhagic disorders! Thromboembolic events are a common and potentially serious complication in cancer. Patients with primary brain tumours are at high risk for venous or arterial thrombosis. Prophylactic anticoagulation can increase bleeding, so predicting thrombosis risk is crucial for tailoring treatment. In a retrospective study, Rolling et al. examined whether circulating tumour cells (CTCs) were linked to thromboembolic events in 133 patients with glioblastoma multiforme (GBM) [ 1 ]. The authors found an 11 % rate of thromboembolism, but detection of CTCs did not help predict risk. Further research into robust biomarkers is thus needed to guide safe and effective thromboprophylaxis in GBM. Direct oral anticoagulants (DOACs) have transformed the treatment of venous thromboembolism, offering practical advantages and a better safety profile compared to vitamin K antagonists. Still, major bleeding remains a serious concern during DOAC therapy. In a detailed case report, Mair et al. highlight important challenges when monitoring rivaroxaban reversal in a 38-year-old man with life-threatening bleeding after an invasive procedure [ 2 ]. The presented data shows that neither standard anti-Xa activity assays nor high-performance liquid chromatography (HPLC) reliably measure the effect of andexanet alfa, a decoy antidote for direct Xa inhibitors. Point-of-care viscoelastic tests, such as rotational thromboelastometry, may be better suited for monitoring the haemostatic efficacy of andexanet alfa reversal. Vonicog alfa is a recombinant von Willebrand factor (VWF) concentrate with higher specific activity than plasma-derived VWF, thanks to supranormal VWF multimers. It is used for on-demand and preventive treatment, as well as for long-term bleeding prophylaxis, in patients with congenital von Willebrand disease. However, there is limited evidence for its safety and effectiveness in acquired von Willebrand syndrome (AVWS), which is caused by different mechanisms and often features a shortened half-life for infused VWF. Blandinières and colleagues describe the challenging case of an 88-year-old man with refractory AVWS due to Waldenström macroglobulinaemia, who eventually benefited from long-term treatment with vonicog alfa [ 3 ]. Early detection of acquired haemophilia A is essential to manage and prevent life-threatening bleeding and to start immunosuppressive therapy to eliminate factor VIII inhibitors. Belani and Teo report the case of a 79-year-old woman who developed spontaneous facial soft-tissue bleeding, a rare manifestation of acquired haemophilia A [ 4 ]. Congenital haemophilia A (HA) is an X-linked bleeding disorder caused by partial or complete deficiency of factor VIII. With an incidence of 1 in 5,000 to 6,000 male newborns, HA is rare, and population-based data about disease burden and treatment outcomes are limited. Statutory Health Insurance (SHI) claims data are increasingly used to fill this knowledge gap. Kratzer et al. analysed claims data collected between 2017 and 2019 from a German SHI provider to shed light on HA-related resource use, outcomes, and costs [ 5 ]. They found that patients experience significant joint disease and psychological stress, regardless of severity. HA care is also costly, with large variations likely due to individual patient needs. Lower-limb deep vein thrombosis is rare in children, adolescents, and young adults. Sometimes, local compression syndromes play a role in the underlying pathophysiology. May-Thurner syndrome (MTS) occurs when the left common iliac vein is compressed by the right common iliac artery. Because no specific guidelines for managing MTS in younger patients had been available, Cuntz et al. conducted an online survey among members of the Society for Thrombosis and Haemostasis Research (GTH) e. V. [ 6 ]. The survey revealed different diagnostic and treatment approaches among 33 experts from Germany, Austria, and Switzerland, highlighting the need for prospective studies to develop evidence-based clinical practice guidelines. The study also emphasises the value of collaboration within an international research society. Development of inhibitors against factor VIII or IX is a serious treatment-emergent complication in haemophilia A and B, respectively. Intravenous access devices, such as port-a-cath systems, may be needed in infants and young children, but procedures like catheter placement or removal carry a high bleeding risk. In a retrospective study, Woestemeier et al. compared the outcomes of 69 port catheter operations in haemophilia patients with inhibitors to 51 procedures in a control group [ 7 ]. Using a standard protocol for recombinant activated factor VII in the haemophilia group, the authors found no significant differences in surgical or bleeding outcomes. However, hospital stays were longer among haemophilia patients. The study underscores the importance of coordinated care within a multidisciplinary team for these complex cases. We hope you enjoy this issue of the journal as much as we did. Our heartfelt thanks go to all the authors and research groups for their thought-provoking original contributions. Florian Langer, Manuela Albisetti and Heiko Rühl for the editorial team Publication History Article published online: 21 April 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Autor:innen und Institutionen

  • Zentrum für Onkologie, II. Medizinische Klinik und Poliklinik (Gerinnungsambulanz und Hämophiliezentrum), Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
  • Institut für Experimentelle Hämatologie und Transfusionsmedizin, Universitätsklinikum Bonn, Bonn, Germany.
  • Institut für Klinische Hämostaseologie und Transfusionsmedizin, Universität des Saarlandes, Homburg, Germany.

Zitieren

APA

Langer, F., Rühl, H., & Albisetti, M. (2026). From Case Reports to Cohort Studies: The Many Faces of Clinical Research in Thrombosis and Haemostasis. Hämostaseologie, 46(02), 96-98. https://doi.org/10.1055/a-2785-1481

Vancouver

Langer F, Rühl H, Albisetti M. From Case Reports to Cohort Studies: The Many Faces of Clinical Research in Thrombosis and Haemostasis. Hämostaseologie. 2026;46(02):96-98. doi:10.1055/a-2785-1481

BibTeX
@article{Langer2026,
  author = {Langer, Florian and Rühl, Heiko and Albisetti, Manuela},
  title = {From Case Reports to Cohort Studies: The Many Faces of Clinical Research in Thrombosis and Haemostasis},
  journal = {Hämostaseologie},
  year = {2026},
  volume = {46},
  number = {02},
  pages = {96--98},
  doi = {10.1055/a-2785-1481}
}
Kostenlos starten →